undamentalytics Newsletter
Sign in

X4 Pharmaceuticals, Inc cash flow statement

In fiscal 2025, X4 Pharmaceuticals, Inc's operations generated −$85.6m of cash; it spent $0 on capital projects, leaving free cash flow of −$85.6m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−25−48−59−71−77−97−131−86−84
Depreciation and amortisation000010112
Stock-based pay125659849
Capital spending001100000
Free cash flow−25−48−60−72−77−97−131−86−84
Free cash flow after stock pay−26−50−66−78−82−105−139−90−92
Share buybacks—00200———
Shares issued—————600239—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KROS vs XFORALEC vs XFORPRQR vs XFOR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from X4 Pharmaceuticals, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to X4 Pharmaceuticals, Inc.